An Eight-Week, Multicenter, Double-Blind, Placebo- and Paroxetine-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Generalized Anxiety Disorder.
Phase of Trial: Phase II
Latest Information Update: 27 May 2016
At a glance
- Drugs Paroxetine; SSR 149415
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Sanofi
- 25 Jul 2011 Actual initiation date changed from Sep 2006 to Aug 2006 as reported by ClinicalTrials.gov.
- 25 Nov 2008 Status changed from active, no longer recruiting to completed.
- 14 Nov 2008 Actual end date added, as reported by clinicaltrials.gov.